Marbofloxacin

	WikiDoc Resources for Marbofloxacin
Articles
Most recent articles on Marbofloxacin Most cited articles on Marbofloxacin Review articles on Marbofloxacin Articles on Marbofloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Marbofloxacin Images of Marbofloxacin Photos of Marbofloxacin Podcasts & MP3s on Marbofloxacin Videos on Marbofloxacin
Evidence Based Medicine
Cochrane Collaboration on Marbofloxacin Bandolier on Marbofloxacin TRIP on Marbofloxacin
Clinical Trials
Ongoing Trials on Marbofloxacin at Clinical Trials.gov Trial results on Marbofloxacin Clinical Trials on Marbofloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Marbofloxacin NICE Guidance on Marbofloxacin NHS PRODIGY Guidance FDA on Marbofloxacin CDC on Marbofloxacin
Books
Books on Marbofloxacin
News
Marbofloxacin in the news Be alerted to news on Marbofloxacin News trends on Marbofloxacin
Commentary
Blogs on Marbofloxacin
Definitions
Definitions of Marbofloxacin
Patient Resources / Community
Patient resources on Marbofloxacin Discussion groups on Marbofloxacin Patient Handouts on Marbofloxacin Directions to Hospitals Treating Marbofloxacin Risk calculators and risk factors for Marbofloxacin
Healthcare Provider Resources
Symptoms of Marbofloxacin Causes & Risk Factors for Marbofloxacin Diagnostic studies for Marbofloxacin Treatment of Marbofloxacin
Continuing Medical Education (CME)
CME Programs on Marbofloxacin
International
Marbofloxacin en Espanol Marbofloxacin en Francais
Business
Marbofloxacin in the Marketplace Patents on Marbofloxacin
Experimental / Informatics
List of terms related to Marbofloxacin

Marbofloxacin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	oral
ATCvet code	Template:Infobox drug/formatATCvet; Template:Infobox drug/formatATCvet;
Legal status
Legal status	Veterinary use only;
Identifiers
	IUPAC name 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol(3,2,1-ij)(4,2,1)benzoxadiazin-6 carboxylic acid;
CAS Number	115550-35-1 ;
ChemSpider	54663 ;
UNII	8X09WU898T;
ChEMBL	ChEMBL478120 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H19FN4O4
Molar mass	362.356
3D model (JSmol)	Interactive image;
	SMILES Fc4cc1c2N(/C=C(\C1=O)C(=O)O)N(COc2c4N3CCN(C)CC3)C;
	InChI InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25) ; Key:BPFYOAJNDMUVBL-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Marbofloxacin is a carboxylic acid derivative third generation fluoroquinolone antibiotic. It is used in veterinary medicine under the trade names Marbocyl,Forcyl and Zeniquin. A formulation of marbofloxacin combined with clotrimazole and dexamethasone is available under the name Aurizon (CAS number 115550-35-1).

Mechanism of action

Its mechanism of action is not thoroughly understood, but it is believed to be similar to the other fluoroquinolones by impairing the bacterial DNA gyrase which results in rapid bactericidal activity.^[1] The other proposed mechanisms include that it acts against nondividing bacteria and does not require protein and RNA synthesis, which block protein and RNA synthesis respectively.^[2]

Activity

Marbofloxacin is a synthetic, broad spectrum bactericidal agent. The bactericidal activity of marbofloxacin is concentration dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Like other fluoroquinolones, marbofloxacin has demonstrated a significant post-antibiotic effect for both gram–and + bacteria and is active in both stationary and growth phases of bacterial replication.^[3]

It has good activity against many gram-negative bacilli and cocci, is effective against:

Pseudomonas aeruginosa

Chlamydia trachomatis

Staphylococci (including penicillinase-producing and methicillin-resistant strains)

Mycoplasma

Mycobacterium

Application

Marbofloxacin can be used both orally and topically. It is particularly used for infections of the skin, respiratory system and mammary glands in dogs and cats, as well as with urinary tract infections. For dogs, a dose ranges from 2.75 - 5.5 mg/kg once a day. The duration of treatment is usually at least five days, longer if there is a concurrent fungal or yeast infection.^[4] Maximum duration of treatment is 30 days.^[3]

Contraindications and side effects

Marbofloxacin should usually be avoided in young animals because of potential cartilage abnormalities. In rare occasion, it can cause CNS stimulation and should be used with caution in patients with seizure disorders.^[3] Under certain conditions it can cause discomfort such as cramps, treatable with diazepam. Other adverse effects are usually limited to GI distress (vomiting, anorexia, soft stools, diarrhoea) and decreased activity.^[3]

References

↑ Boothe, D.M. (2001) Antimicrobial drugs. In Small Animal ClinicalPharmacology and Therapeutics, pp. 150–173. W. B. Saunders Co.,Philadelphia, PA.
↑ Hunter RP, Koch DE, Coke RL, Carpenter JW, Isaza R. Identification and comparison of marbofloxacin metabolites from the plasma of ball pythons (Python regius) and blue and gold macaws (Ara ararauna). J Vet Pharmacol Ther. 2007 Jun;30(3):257-62.
↑ ^3.0 ^3.1 ^3.2 ^3.3 Plumb DC (ed). Plumb's Veterinary Handbook, 7th ed. Ames, IA: Wiley-Blackwell Publishing, 2011.
↑ Rougier S, Borell D, Pheulpin S, Woehrlé F, Boisramé B (October 2005). "A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa". Vet. Dermatol. 16 (5): 299–307. doi:10.1111/j.1365-3164.2005.00465.x. PMID 16238809.

External links

vetpharm.unizh.ch

Template:QuinoloneAntiBiotics

[1] Boothe, D.M. (2001) Antimicrobial drugs. In Small Animal ClinicalPharmacology and Therapeutics, pp. 150–173. W. B. Saunders Co.,Philadelphia, PA.

[2] Hunter RP, Koch DE, Coke RL, Carpenter JW, Isaza R. Identification and comparison of marbofloxacin metabolites from the plasma of ball pythons (Python regius) and blue and gold macaws (Ara ararauna). J Vet Pharmacol Ther. 2007 Jun;30(3):257-62.

[:0-3] 3.0 ^3.1 ^3.2 ^3.3 Plumb DC (ed). Plumb's Veterinary Handbook, 7th ed. Ames, IA: Wiley-Blackwell Publishing, 2011.

[pmid16238809-4] Rougier S, Borell D, Pheulpin S, Woehrlé F, Boisramé B (October 2005). "A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa". Vet. Dermatol. 16 (5): 299–307. doi:10.1111/j.1365-3164.2005.00465.x. PMID 16238809.

[1]

[2]

[3]

[4]